Under the agreement, Aspen will manufacture Gilead’s antiretroviral (ARV) products Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate) for the 95 resource-limited countries included in Gilead’s global access program and distribute the products in every country in Africa.
Gilead will provide active pharmaceutical ingredient (API) for its products to Aspen and will transfer the necessary technology for tableting of the products in Aspen’s FDA-approved facilities in South Africa.
In addition, Aspen will pursue regulatory approval for the products in the countries in Africa where one or both products are not already registered.
Aspen has agreed to sell the products at the current prices established through Gilead’s global access program but, as economies of scale and process improvements are achieved, these prices may be further reduced.